TB/HIV research meeting

WHO in collaboration with the Consortium to Respond Effectively to the AIDS/TB Epidemic (CREATE) and the TB/HIV Working Group of the Stop TB Partnership is organizing the 7^th CROI affiliated HIV/TB research meeting which will be held on Sunday 3 March 2013 in Atlanta, USA. The aim of the meeting is to promote high level scientific interchange of ideas and research priorities about specific issues related TB prevention as well as drug interactions between new TB drugs and ART. 

A third of all people living with HIV worldwide are latently infected with Mycobacteria tuberculosis, making them 21-34 times more likely to develop active TB disease than people who are HIV negative. Despite being preventable and curable, TB is still a leading killer of people living with HIV, with a quarter of all HIV deaths found to be TB-related. This meeting will share data from on-going studies, discuss controversial issues and identify critical research questions. Areas of focus will be on the impact of Isoniazid Preventive Therapy among infants and children living with HIV, rifapentine for TB prevention among people living with HIV, as well as drug interactions of new ART and TB drugs. Please see the provisional agenda of the meeting below.

The meeting is intended for HIV researchers, implementers and public health policy makers. A light lunch will be served during the meeting. Attendance of the meeting will be by confirmed registration only and on a first come, first serve basis. If you are interested in participating please send an e-mail expressing your interest to [email protected] at your earliest convenience but no later than close of business on February 22, 2013.

Tentative Agenda

Convener: Haileyesus Getahun (Stop TB Department, WHO)

Co-chairs: Diane Havlir, (Chair of the Global TB/HIV Working Group and UCSF, USA) and Richard Chaisson, (Johns Hopkins University, USA)

11:30-11:35:  Introduction and objectives of the meeting

Diane Havlir

11:35-11:50:

Isoniazid preventive therapy for children: impact on mortality and incidence of tuberculosis

Charles Mitchell, University of Miami, Miami, FL, USA

11:50-11:55:

Commentary

Mark Cotton, University of Stellenbosch, South Africa

11:55-12:10:

Rifapentine to prevent TB among people living with HIV: interim data and pending issues

Timothy Sterling, Vanderbilt University, Nashville, TN, USA

12:10-12:15:

Commentary

Neil Martinson, PHRU, Chris Hani Baragwanath Hospital, Soweto, South Africa (TBC)

12:15-12:45: Discussion

12:45-13:00: Drug interactions with ART and new TB drugs: What do we know?

Kelly Dooley, Johns Hopkins University School of Medicine, Baltimore, MD, USA

13:00-13:05:

Commentary

Gary Maartens, University of Cape Town Medical School, South Africa

13:05-13:25: Discussion

13:25-13:30: General conclusion and next steps

Diane Havlir